ID   PC-3
AC   CVCL_0035
SY   PC3; PC.3
DR   BTO; BTO:0001061
DR   CLO; CLO_0008395
DR   CLO; CLO_0051535
DR   EFO; EFO_0002074
DR   MCCL; MCC:0000380
DR   CLDB; cl3881
DR   CLDB; cl3883
DR   Abcam; ab275472
DR   AddexBio; C0019002/61
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1435
DR   ATCC; CRL-7934
DR   BCRC; 60122
DR   BCRJ; 0269
DR   BioGRID_ORCS_Cell_line; 193
DR   BioSample; SAMN01821588
DR   BioSample; SAMN01821653
DR   BioSample; SAMN01821713
DR   BioSample; SAMN03472063
DR   BioSample; SAMN05292438
DR   BioSample; SAMN10988356
DR   cancercelllines; CVCL_0035
DR   CCRID; 1101HUM-PUMC000115
DR   CCRID; 3101HUMSCSP532
DR   CCRID; 3101HUMTCHu158
DR   CCRID; 4201HUM-CCTCC00095
DR   CCTCC; GDC0095
DR   Cell_Model_Passport; SIDM00088
DR   ChEMBL-Cells; CHEMBL3307570
DR   ChEMBL-Targets; CHEMBL390
DR   CLS; 300312
DR   Cosmic; 688118
DR   Cosmic; 704849
DR   Cosmic; 713868
DR   Cosmic; 719680
DR   Cosmic; 721366
DR   Cosmic; 721556
DR   Cosmic; 755297
DR   Cosmic; 759894
DR   Cosmic; 801350
DR   Cosmic; 809225
DR   Cosmic; 850414
DR   Cosmic; 869157
DR   Cosmic; 873002
DR   Cosmic; 875892
DR   Cosmic; 876396
DR   Cosmic; 897455
DR   Cosmic; 905934
DR   Cosmic; 911997
DR   Cosmic; 918502
DR   Cosmic; 920968
DR   Cosmic; 921048
DR   Cosmic; 922551
DR   Cosmic; 923957
DR   Cosmic; 943175
DR   Cosmic; 948379
DR   Cosmic; 949249
DR   Cosmic; 974299
DR   Cosmic; 1028650
DR   Cosmic; 1028702
DR   Cosmic; 1071477
DR   Cosmic; 1075273
DR   Cosmic; 1092627
DR   Cosmic; 1172628
DR   Cosmic; 1175888
DR   Cosmic; 1188436
DR   Cosmic; 1212489
DR   Cosmic; 1219448
DR   Cosmic; 1305380
DR   Cosmic; 1312367
DR   Cosmic; 1330910
DR   Cosmic; 1436048
DR   Cosmic; 1689714
DR   Cosmic; 1995613
DR   Cosmic; 1998469
DR   Cosmic; 2301588
DR   Cosmic; 2580130
DR   Cosmic; 2585153
DR   Cosmic; 2585230
DR   Cosmic; 2621167
DR   Cosmic; 2651772
DR   Cosmic; 2669172
DR   Cosmic; 2674178
DR   Cosmic-CLP; 905934
DR   DepMap; ACH-000090
DR   DSMZ; ACC-465
DR   DSMZCellDive; ACC-465
DR   ECACC; 90112714
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS420VDY
DR   ENCODE; ENCBS451OVM
DR   ENCODE; ENCBS504WVV
DR   ENCODE; ENCBS596CTT
DR   ENCODE; ENCBS608AAA
DR   ENCODE; ENCBS609AAA
DR   FCS-free; 16-2-16-3-6-4
DR   GDSC; 905934
DR   GEO; GSM2171
DR   GEO; GSM50225
DR   GEO; GSM50289
DR   GEO; GSM91930
DR   GEO; GSM142459
DR   GEO; GSM142460
DR   GEO; GSM482670
DR   GEO; GSM525804
DR   GEO; GSM595615
DR   GEO; GSM648823
DR   GEO; GSM743480
DR   GEO; GSM750835
DR   GEO; GSM784792
DR   GEO; GSM799370
DR   GEO; GSM799433
DR   GEO; GSM847110
DR   GEO; GSM844675
DR   GEO; GSM844674
DR   GEO; GSM887506
DR   GEO; GSM888588
DR   GEO; GSM1153442
DR   GEO; GSM1178542
DR   GEO; GSM1178543
DR   GEO; GSM1181274
DR   GEO; GSM1181303
DR   GEO; GSM1374817
DR   GEO; GSM1374818
DR   GEO; GSM1670339
DR   GEO; GSM2124647
DR   GEO; GSM4962583
DR   GEO; GSM4962584
DR   GEO; GSM4962585
DR   GEO; GSM4962586
DR   GEO; GSM4962587
DR   GEO; GSM4962588
DR   GEO; GSM4962589
DR   GEO; GSM4962590
DR   GEO; GSM4962591
DR   IARC_TP53; 752
DR   IARC_TP53; 21276
DR   ICLC; HTL97018
DR   IZSLER; BS TCL 175
DR   JCRB; JCRB9110
DR   KCB; KCB 200725YJ
DR   KCLB; 21435
DR   LiGeA; CCLE_525
DR   LINCS_HMS; 50454
DR   LINCS_LDP; LCL-1299
DR   Lonza; 125
DR   MeSH; D000078722
DR   NCBI_Iran; C427
DR   NCI-DTP; PC-3
DR   PharmacoDB; PC3_1248_2019
DR   PRIDE; PRD000228
DR   PRIDE; PRD000597
DR   PRIDE; PXD000661
DR   PRIDE; PXD002107
DR   PRIDE; PXD003105
DR   PRIDE; PXD005940
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD008184
DR   PRIDE; PXD030304
DR   PRIDE; PXD032264
DR   Progenetix; CVCL_0035
DR   PubChem_Cell_line; CVCL_0035
DR   RCB; RCB2145
DR   SKY/M-FISH/CGH; 2799
DR   TKG; TKG 0600
DR   TOKU-E; 2868
DR   Ubigene; YC-C010
DR   Wikidata; Q7118483
RX   CelloPub=CLPUB00698;
RX   DOI=10.4172/2157-7145.S2-005;
RX   PubMed=447482;
RX   PubMed=571045;
RX   PubMed=1873816;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=6244232;
RX   PubMed=8104329;
RX   PubMed=8687134;
RX   PubMed=9018337;
RX   PubMed=9823299;
RX   PubMed=10700174;
RX   PubMed=10702678;
RX   PubMed=10754530;
RX   PubMed=10972993;
RX   PubMed=11135431;
RX   PubMed=11172901;
RX   PubMed=11304728;
RX   PubMed=11414198;
RX   PubMed=11416159;
RX   PubMed=12606952;
RX   PubMed=12725112;
RX   PubMed=14518029;
RX   PubMed=15486987;
RX   PubMed=15748285;
RX   PubMed=17088437;
RX   PubMed=17254797;
RX   PubMed=17440963;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=21432867;
RX   PubMed=22068913;
RX   PubMed=22275356;
RX   PubMed=22336246;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=23671654;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24504141;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26256267;
RX   PubMed=26589293;
RX   PubMed=26972028;
RX   PubMed=27141528;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=30244336;
RX   PubMed=30787054;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31404090;
RX   PubMed=31978347;
RX   PubMed=32968452;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/PC3
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://www.atcc.org/en/support/technical-support/faqs/morphology-of-atcc-crl-1435
WW   https://www.synapse.org/#!Synapse:syn31544570
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=53
WW   https://www.proteinatlas.org/learn/cellines
WW   https://web.archive.org/web/20160328064204/http://capcelllines.ca/details.asp?id=37
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-96.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 25.34 +- 0.02 hours (PubMed=32968452); 25 hours (ATCC=CRL-7934); 40 +- 10 hours (CLS=300312); ~50 hours (DSMZ=ACC-465); 27.1 hours (NCI-DTP=PC-3); ~25 hours (PBCF).
CC   HLA typing: A*01:01:01,24:02:01; B*13:02,55:01; C*01,06; DPB1*04:01; DQB1*02:02,06:03; DRB1*07:01,13:01:01 (PubMed=15748285).
CC   HLA typing: A*01:01,24:01; B*13:02,55:01; C*01:02,06:02 (PubMed=25960936).
CC   HLA typing: A*01:01,24:02; B*13:02,55:01; C*01:02,06:02; DRB1*13:01,13:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=1873816; PubMed=8104329; PubMed=17088437; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Secretome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.41%; Native American=0%; East Asian, North=0.52%; East Asian, South=0%; South Asian=1.19%; European, North=65.73%; European, South=32.14% (PubMed=30894373).
CC   Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C427.
CC   Discontinued: ATCC; CRL-7934; true.
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DOI=10.4172/2157-7145.S2-005; DSMZ; ECACC; Genomics_Center_BCF_Technion; JCRB; KCLB; PubMed=11416159; PubMed=14518029; PubMed=17254797; PubMed=19372543; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D10S1248: 16
ST   D12S391: 21
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 13,14 (PubMed=17254797)
ST   D18S51: 14,15 (CCRID; CLS; DOI=10.4172/2157-7145.S2-005; DSMZ; Genomics_Center_BCF_Technion; PubMed=11416159; PubMed=14518029; PubMed=19372543; PubMed=25877200)
ST   D19S433: 14
ST   D1S1656: 12,16
ST   D21S11: 29,31 (PubMed=17254797)
ST   D21S11: 29,31.2 (CCRID; CLS; DOI=10.4172/2157-7145.S2-005; DSMZ; Genomics_Center_BCF_Technion; PubMed=11416159; PubMed=14518029; PubMed=19372543; PubMed=25877200)
ST   D22S1045: 15
ST   D2S1338: 18,20 (CCRID; DOI=10.4172/2157-7145.S2-005; Genomics_Center_BCF_Technion; PubMed=19372543)
ST   D2S1338: 20 (DSMZ)
ST   D2S441: 10,11
ST   D3S1358: 16
ST   D5S818: 13 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DOI=10.4172/2157-7145.S2-005; DSMZ; ECACC; KCLB; PubMed=14518029; PubMed=17254797; PubMed=19372543; PubMed=25877200; RCB; TKG)
ST   D5S818: 13,14 (Genomics_Center_BCF_Technion)
ST   D7S820: 8 (PubMed=17254797; TKG)
ST   D7S820: 8,11 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DOI=10.4172/2157-7145.S2-005; DSMZ; ECACC; Genomics_Center_BCF_Technion; JCRB; KCLB; PubMed=14518029; PubMed=19372543; PubMed=25877200; RCB)
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 9
ST   Penta E: 10,17
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 47
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
//
RX   DOI=10.4172/2157-7145.S2-005;
RA   Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.,
RA   Hart R.P., Furtado M.R.;
RT   "STR profiling of human cell lines: challenges and possible solutions
RT   to the growing problem.";
RL   J. Forensic Res. 2 Suppl. 2:5-5(2011).
//
RX   PubMed=447482;
RA   Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W.;
RT   "Establishment and characterization of a human prostatic carcinoma
RT   cell line (PC-3).";
RL   Invest. Urol. 17:16-23(1979).
//
RX   PubMed=571045;
RA   Kaighn M.E., Lechner J.F., Narayan K.S., Jones L.W.;
RT   "Prostate carcinoma: tissue culture cell lines.";
RL   Natl. Cancer Inst. Monogr. 49:17-21(1978).
//
RX   PubMed=1873816;
RA   Isaacs W.B., Carter B.S., Ewing C.M.;
RT   "Wild-type p53 suppresses growth of human prostate cancer cells
RT   containing mutant p53 alleles.";
RL   Cancer Res. 51:4716-4720(1991).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=8104329; DOI=10.1002/pros.2990230206;
RA   Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.;
RT   "p53 oncogene mutations in three human prostate cancer cell lines.";
RL   Prostate 23:123-134(1993).
//
RX   PubMed=8687134;
RA   Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.;
RT   "The effects of omega-3 and omega-6 fatty acids on in vitro prostate
RT   cancer growth.";
RL   Anticancer Res. 16:815-820(1996).
//
RX   PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H;
RA   Webber M.M., Bello D., Quader S.T.A.;
RT   "Immortalized and tumorigenic adult human prostatic epithelial cell
RT   lines: characteristics and applications Part 2. Tumorigenic cell
RT   lines.";
RL   Prostate 30:58-64(1997).
//
RX   PubMed=9823299;
RA   Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T.,
RA   Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.;
RT   "Gene expression profiling of alveolar rhabdomyosarcoma with cDNA
RT   microarrays.";
RL   Cancer Res. 58:5009-5013(1998).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10702678; DOI=10.1159/000015432;
RA   Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.,
RA   Isola J., Visakorpi T., Bergerheim U.S.R., Larsson C.;
RT   "Characterization of chromosomal abnormalities in prostate cancer cell
RT   lines by spectral karyotyping.";
RL   Cytogenet. Cell Genet. 87:225-232(1999).
//
RX   PubMed=10754530; DOI=10.1002/(SICI)1097-0045(20000501)43:2<144::AID-PROS9>3.0.CO;2-H;
RA   Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., Imura N.;
RT   "Role of antioxidant systems in human androgen-independent prostate
RT   cancer cells.";
RL   Prostate 43:144-149(2000).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E;
RA   Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.;
RT   "IPM-FISH, a new M-FISH approach using IRS-PCR painting probes:
RT   application to the analysis of seven human prostate cell lines.";
RL   Genes Chromosomes Cancer 30:143-160(2001).
//
RX   PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3;
RA   Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.;
RT   "The use of multicolor fluorescence technologies in the
RT   characterization of prostate carcinoma cell lines: a comparison of
RT   multiplex fluorescence in situ hybridization and spectral karyotyping
RT   data.";
RL   Cancer Genet. Cytogenet. 124:112-121(2001).
//
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=12606952; DOI=10.1038/sj.onc.1206247;
RA   Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I.,
RA   Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.;
RT   "Genome-wide screening for complete genetic loss in prostate cancer by
RT   comparative hybridization onto cDNA microarrays.";
RL   Oncogene 22:1247-1252(2003).
//
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
//
RX   PubMed=14518029; DOI=10.1002/pros.10290;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U.,
RA   Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.;
RT   "Molecular characterization of human prostate carcinoma cell lines.";
RL   Prostate 57:205-225(2003).
//
RX   PubMed=15486987; DOI=10.1002/pros.20158;
RA   Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R.,
RA   Brooks J.D.;
RT   "Genome-wide characterization of gene expression variations and DNA
RT   copy number changes in prostate cancer cell lines.";
RL   Prostate 63:187-197(2005).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Tehrani M.J., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=17440963; DOI=10.1002/pros.20581;
RA   Takeda M., Mizokami A., Mamiya K., Li Y.-Q., Zhang J., Keller E.T.,
RA   Namiki M.;
RT   "The establishment of two paclitaxel-resistant prostate cancer cell
RT   lines and the mechanisms of paclitaxel resistance with two cell
RT   lines.";
RL   Prostate 67:955-967(2007).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21432867; DOI=10.1002/pros.21383;
RA   Tai S., Sun Y., Squires J.M., Zhang H., Oh W.K., Liang C.-Z.,
RA   Huang J.-T.;
RT   "PC3 is a cell line characteristic of prostatic small cell
RT   carcinoma.";
RL   Prostate 71:1668-1679(2011).
//
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
//
RX   PubMed=22275356; DOI=10.1074/jbc.M111.302547;
RA   Lynch T.P., Ferrer C.M., Jackson S.R., Shahriari K.S., Vosseller K.,
RA   Reginato M.J.;
RT   "Critical role of O-linked beta-N-acetylglucosamine transferase in
RT   prostate cancer invasion, angiogenesis, and metastasis.";
RL   J. Biol. Chem. 287:11070-11081(2012).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D.-X., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
//
RX   PubMed=24504141; DOI=10.3892/ijo.2014.2287;
RA   Suetens A., Moreels M., Quintens R., Chiriotti S., Tabury K.,
RA   Michaux A., Gregoire V., Baatout S.;
RT   "Carbon ion irradiation of the human prostate cancer cell line PC3: a
RT   whole genome microarray study.";
RL   Int. J. Oncol. 44:1056-1072(2014).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26256267; DOI=10.1074/mcp.M115.047928;
RA   Shah P., Wang X.-C., Yang W.-M., Toghi Eshghi S., Sun S.-S., Hoti N.,
RA   Chen L.-J., Yang S., Pasay J., Rubin A., Zhang H.;
RT   "Integrated proteomic and glycoproteomic analyses of prostate cancer
RT   cells reveal glycoprotein alteration in protein abundance and
RT   glycosylation.";
RL   Mol. Cell. Proteomics 14:2753-2763(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30244336; DOI=10.1007/s00345-018-2501-6;
RA   Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D.,
RA   Sahin A., Balci F.;
RT   "Paclitaxel resistance and the role of miRNAs in prostate cancer cell
RT   lines.";
RL   World J. Urol. 37:1117-1126(2019).
//
RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;
RA   Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P.,
RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.A.;
RT   "Genetic ancestry analysis reveals misclassification of commonly used
RT   cancer cell lines.";
RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31404090; DOI=10.1371/journal.pone.0220807;
RA   Jeon J.M., Kwon O.K., Na A.-Y., Sung E.J., Cho I.J., Kim M., Yea S.S.,
RA   Chun S.Y., Lee J.H., Ha Y.-S., Kwon T.G., Lee S.;
RT   "Secretome profiling of PC3/nKR cells, a novel highly migrating
RT   prostate cancer subline derived from PC3 cells.";
RL   PLoS ONE 14:E0220807-E0220807(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32968452; DOI=10.3892/ol.2020.12093;
RA   Liu J., Huang Y.-J., Zhu D.-Y., Dai Y., Liu D., Zhai Y., Liang X.-G.,
RA   Wu L.-H., Zhao Q.-W.;
RT   "Establishment and characterization of a docetaxel-resistant human
RT   prostate cancer cell line.";
RL   Oncol. Lett. 20:230.1-230.7(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//